Insight & Intelligence

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

April 15, 2011 (Vol. 31, No. 8)

Managing PTMs in Protein Therapeutics

Ultimate Success of Biosimilars Linked to Adroit Handling of Post-Translational Modifications

  • As more and more biopharmaceuticals move along the torturous process of development, clinical evaluation, and approval, dealing with changes to these complex protein molecules becomes increasingly paramount. A number of meetings and symposia have examined this question lately, and it’s clear that the technology is ramping up to successfully ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.